1. SYNOPSIS. AWB-ML21645 Date: April 20, 2016 Title of the observational study
|
|
- Joseph Lawrence
- 5 years ago
- Views:
Transcription
1 1. SYNOPSIS AWB-ML21645 Date: April 20, 2016 Title of the observational study INVESTIGATORS SPONSOR Noninterventional study on the quality assurance of the therapy of chronic hepatitis C with Peg-(40kd)-Interferon alfa-2a (Pegasys ) and Ribavirin (e.g. Copegus ) with main focus gastroenterologists a project in bng, Part III The documentation was performed at 515 sites (444 officebased physicians and 71 clinic physicians) distributed over the entire area of the Federal Republic of Germany. Roche Pharma AG, Emil-Barell-Str Grenzach-Wyhlen MATERIAL AND METHODS Study population Ethics Study design Study objectives Men and women from 18 years of age with chronic active virus hepatitis C with substantiated virus replication. Inclusion criteria: Patients of both genders at an age 18 years Chronic active virus hepatitis C with substantiated virus replication Exclusion criteria: Pregnancy, breastfeeding or women at an age able to conceive without reliable contraception of the woman or the partner. Contraindications for the application of Pegasys, as well as with combination therapy for the application of Ribavirin (e.g. Copegus ) A positive vote of the ethics committee of the Westphalia- Lippe medical association and the medical faculty of the Westphalian Wilhelms-University Münster is available. National, multicentre, open-label, noninterventional study. Primary study objectives Investigation of the effectiveness and tolerability of the therapy of chronic hepatitis C with Peg-Interferon alfa-2a (Pegasys ), usually in the combination with Ribavirin (Copegus ), with patients who are being treated by gastroenterologists at main focus practices, respectively day clinics under everyday conditions. Secondary study objectives Gaining of understanding about the therapeutic habits with hepatitis C and about the compliance of the patients. In harmonisation with the existing recommendations, development of measures for quality improvement in the care of hepatitis C patients. Cause and error analyses for individual practices and clinic day clinics, to optimise the general care quality with the therapy of hepatitis C with Peg-Interferon alfa- Clinical Study Report ML Report Number 1 - v1.5, April 20 th 2016 Page 15 of 234
2 2a (Pegasys ) and Ribavirin (Copegus ). Systematic recording of understanding on the safety profile of Peg-Interferon alfa-2a (Pegasys ) and Ribavirin (Copegus ). Investigational medicinal product & treatment Duration of the study Statistical methodology Pegasys 135 micrograms, respectively 180 micrograms injection solution in a ready to use syringe for injection once a week in combination with the oral administration of Ribavirin. Start of the noninterventional study: January 01, 2008 (First- Patient-In, FPI). End of the observational study was on September 26, 2013 (Last-Patient-Out, LPO). The end of inclusion (Last-Patient-In, LPI) was initially planned for December 31, 2009, was however, extended by amendment until December 31, All collected data are descriptively summarised using mean, standard deviation, minimum, maximum, median, 1st and 3rd Quartile for quantitative data and absolute and relative frequencies (percentages) for qualitative data. For the tolerability analysis adverse drug reactions are provided displaying the number and proportion of patients with at least one event by MedDRA preferred term and system organ class. These overview tables were additionally stratified by seriousness. RESULTS Patient disposition The analysis presented here is based on the data from 9620 patients, who were surveyed within the scope of a noninterventional study (NIS) on the therapy of chronic hepatitis C with Pegasys and Ribavirin and with whom the documentation was completed by the investigator (main analysis set). In 26.5% of all patients treated with Pegasys the treatment was prematurely discontinued. The most frequent reasons for a therapy discontinuation were deficient virological response (42.3% of the patients with therapy discontinuation) and lost-to-follow-up (21.2%). In 63.7% of the patients the treatment was completed as planned, in 9.8% of the patients the documentation of the therapy was not completed within the scope of the observation time period. Demographic data and original data 66.0% of the patients were of male and 34.0% of female gender. The mean (±SD) age was 42.2 (±11.4) years. The mean height was (±9.1) cm and the mean body weight was 76.7 (±14.8) kg. The mean Body Mass Index (BMI) was 25.4 (±4.3) kg/m 2. A proportion of 35.8% of the patients were shown to have a different native language than German, in most cases Russian (20.7%). In approximately 8.1% of the patients knowledge of the German language was either not present or only poor. For Russian, Turkish respectively English speaking patients a patient information and declaration of Clinical Study Report ML Report Number 1 - v1.5, April 20 th 2016 Page 16 of 234
3 informed consent was available in the respective language. In 59.2% of the patients an infection with the HC-Virus genotype 1 was present, in 5.7% there was a genotype 2 infection, in 30.2% a genotype 3 infection, in 4.4% a genotype 4 infection, and in respectively 0.2% a genotype 5 infection, respectively genotype 6 infection was present (in 0.2% of the patients a genotyping was missing). The proportion of the patients with high virus burden (HCV- RNA > 400,000 IU/ml) was at 60.0%. I.v. drug abuse (43.8%) and blood products (10.6%) were the most frequently documented means of transmission for a hepatitis C infection. In 31.6% of the patients the cause of the infection was unknown. The median duration of infection was 10.0 years. At the entry examination clinical signs for cirrhosis of the liver were found in 4.8% (n=457/9620) of all patients. In 63.3% of the patients concomitant diseases were reported. The most frequently documented diseases were drug and/or alcohol abuse (50.9%), psychiatric diseases (25.9%) and cardiovascular diseases (14.1%). 86.7% of the patients were not pre-treated with an anti-viral therapy, 6.9% were therapy relapsers and 5.1% were nonresponders to a previous hepatitis C therapy. Medication Effectiveness The median starting dosage of Pegasys was 180 µg/week in patients with the virus genotype 1/4/5/6, as well as also in patients with genotype 2/3. The median treatment duration with Pegasys was 47 weeks in genotype 1/4/5/6 patients and 24.1 weeks in genotype 2/3 patients. In most cases Copegus was prescribed as Ribavirin in the combination with Pegasys (95.5%; n=9161/9591). The median starting dosage of Ribavirin was 1200 mg/d for the genotype 1/4/5/6 infected, and 1000 mg/d for the genotype 2/3 infected patients. The PEG-RBV combination therapy was discontinued in 26.5% (n=2549/9620) of the patients. 63.7% (n=6131/9620) of the patients reached the planned end of the therapy with the PEG-RBV combination therapy. The most frequent discontinuation reasons for the PEG-RBV combination therapy were virological nonresponse (42.3%; n=1079/2549) and lost-to-follow-up (21.2%; n=540/2549). After 4 treatment weeks (±5 days) evaluable data on HCV- PCR data, respectively on a possible therapy discontinuation were available for 6442 of the 9620 patients. In 2579 of these patients a virological response was observed, i.e. HCV-RNA viral load was under the limit of detection of used PCR technique. Therefore the Rapid Virological Response (RVR) was 40.0% (n=2579/6442), respectively 26.8% (n=2579/9620) in relation to the main analysis set, i.e. considering all patients still in the study, but without evaluable value as non-responder. After 12 weeks (±10 days) evaluable data on HCV-PCR Clinical Study Report ML Report Number 1 - v1.5, April 20 th 2016 Page 17 of 234
4 data, respectively data on a possible therapy discontinuation were available for 7383 patients. In 5260 of these patients there was a virological response, defined as a HCV-RNA viral load decline under the limit of detection, or as viral load decline 2 log from baseline viral load. This Early Virological Response (EVR) after 12 weeks therapy was 71.2% (n=5260/7383), respectively 54.7% (n=5260/9620) in relation to the main analysis set. At the end of the treatment (EoT) the response rate (EoTR), defined as HCV-RNA viral load undetectable at the end of therapy was 59.2% based on all 9620 patients of the main analysis set (HCV genotype (GT) %; GT %; GT %; GT %; GT %; GT %). The Sustained Virological Response (SVR), defined as HCV-RNA viral load undetectable 24 weeks after the end of treatment was 41.4% based on all patients (n=3979/9620). For patients with GT 1 the SVR was 38.2%, for GT %, for GT %, for GT %, for GT % and for GT %. Tolerability At all visits the following clinical symptoms were solicited: Fatigue/exhaustion, fever, rigor, skin changes, loss of hair, joint pain, muscle pain, abdominal complaints, nausea, reflux, weight loss, headache, sleeplessness, irritability, restlessness, depression, depressive mood, psychosis as well as other symptoms. For all solicited symptoms lower incidences were reported at the follow-up observation 24 weeks after the end of treatment compared to baseline. The compliance was assessed by the treating physicians after 24, 36 and 48 weeks as being "very good (all medication taken)" in approximately 65% of the patients. At the end of the therapy the compliance in 56.4% of the patients was assessed as being "very good (all medication taken)". Over the course of the observational study relevant laboratory parameters were measured at different time points: GPT (=ALT), GOT (= AST), Gamma-GT, haemoglobin, erythrocytes, thrombocytes, leucocytes, neutrophile, TSH, Quick, AP, bilirubin, creatinine, serum ferritin, serum iron, transferrin, Alpha-feto protein, albumin, blood glucose (fasting), HbA1c, triglycerides, cholesterol, HDL, LDL, uric acid, CRP. The levels of the measured values as well as their changes over the course of the observational study were in the expected ranges. For example, at baseline a mean value of U/l was measured for GPT, at EoT a value of 45.7 U/l and at the follow-up a value of 43.8 U/l. In total, 502 serious adverse drug reactions (SADRs) were documented in 341 of the 9620 patients, resulting in an incidence rate of 3.5%. The most frequently reported individual SADRs (based on MedDRA Preferred Terms) were anaemia (0.3%, n=33), pneumonia (0.3%, n=26) and depression (0.2%, n=18). In total, over the course of the Clinical Study Report ML Report Number 1 - v1.5, April 20 th 2016 Page 18 of 234
5 observational study 39 cases of death were recorded. 32 of these were included in the main analysis set. In 16 of these 32 fatal cases a causal relationship with Pegasys was assessed by the investigators. In total, 10 female patients reported pregnancies within this study, 4 of these during the follow-up period. Quality-of-life DISCUSSION The assessment of the quality of life within the scope of the entry examination using the items no impairment, low, moderate or strong showed no impairment in 36.3% of the patients. In comparison to the entry examination an increase of the complaint free patients to 56.8% was shown at the end of the follow-up observation using the categories free of symptoms, improved, but not free of symptoms, unchanged or deteriorated. The mean physical component summary score of the SF-36 Questionnaire was 49 at the entry examination, 45 after approximately 12 weeks,47 at the end of the treatment (EoT) and increased to 51 at the follow-up visit. The mean mental component summary score was 41 at the entry examination, 36 after approximately 12 weeks, 37 at the end of the treatment (EoT) and increased to 44 at the follow-up visit. With 400,000 to 500,000 virus carriers of chronic Hepatitis C (chc) in Germany the observational study presented here with 9620 patients comprises approximately 2% of this patient population. The largest proportion of the patients documented in this study are carriers of genotype 1 (59.2%). At the time of the entry examination 60.0% of the patients had a high viral load. I.v. drug abuse and blood products were the most frequent means of transmission. As 35.8% of the patients have a different native language than German, the improvement of the dialogue between physician and patient, e.g. with suitable translation aids, appears to be an important step towards the improvement of the care. The Sustained Virological Response (SVR) 24 weeks after the end of the treatment was 41.4% based on all patients in the main analysis set with SVR-rates of 38.2% for GT 1 and 34.9% for GT 4, as well as 54.8% for GT 2 and 45.9% for GT 3 patients. The virological response observed under reallife conditions is therefore somewhat lower than the data reported in clinical studies (Fried et al., 2002; Hadziyannis et al., 2004). The documented adverse drug reactions did not reveal any new risks not yet reported in clinical studies. Serious adverse drug reactions occurred in 3.5% of the patients; they were therefore less frequent than the 6% known from clinical studies, which however, may be related to an underreporting within the real-life setting. Over the course of the observational study 39 cases of death were documented. The results of the NIS reveal new insights in the therapy of Hepatitis C in everyday clinical practice: With 35.8% more Clinical Study Report ML Report Number 1 - v1.5, April 20 th 2016 Page 19 of 234
6 CONCLUSIONS than a third of the patients have a different native language than German, in most cases Russian (20.7%). With 43.8% the group of the patients with drug abuse constitutes the largest proportion of the treated HCV patients. 63.3% of the patients had serious concomitant diseases, which represented an exclusion criterion in the marketing authorisation studies. This real-world data reveal that the management of multiple diseases is a component of everyday clinical practice in the care of patients with chronic hepatitis C. The high proportion of patients with very good compliance indicates that within the scope of the therapeutic care it been possible has in many cases to convince the patients about the importance of the therapy, whereby measures of quality improvement such as multilanguage patient information material has probably contributed to this. In this noninterventional study Pegasys alone or in combination with ribavirin showed an effectiveness under real-life conditions almost comparable to the efficacy demonstrated in pivotal clinical trials. The slightly lower response rates with regard to SVR may be attributable to the less controlled study setting with higher drop-out rates or the different patient population included in noninterventional studies based on less strict selection criteria, e.g. patients having more comorbidities. No new hitherto unknown adverse drug reactions were observed. Rates of reported events were lower as observed in clinical trials. This may be due to an underreporting, in particular of non-serious events, which is quite common in observational studies. Overall the data from this noninterventional study does not give any cause to change the current assessment of the benefit-risk profile of Pegasys in the treatment of chronic hepatitis C. Clinical Study Report ML Report Number 1 - v1.5, April 20 th 2016 Page 20 of 234
1.0 Abstract. Title. Keywords
1.0 Abstract Title Real World Evidence of the Effectiveness of Paritaprevir/r Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients with Chronic Hepatitis C - An Observational Study in Austria (REAL) Keywords
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationShort title: BENEFIT STUDY, STUDY REPORT (ML25614) Synopsis/Abstract
A Multicenter, prospective, Non-Interventional Study Evaluating Response Parameters during and after Therapy with PEGASYS (Peginterferon alfa-2a 40KD) in Subjects with HBeAg positive or HBeAg negative
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationCASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?
Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse
More informationRibavirin (Medicare Prior Authorization)
Prior Authorization Form ARKANSAS BLUE CROSS AND BLUE SHIELD Medi-Pak Rx (PDP), Medi-Pak Advantage (PFFS), and Medi-Pak Advantage PPO Ribavirin (Medicare Prior Authorization) This fax machine is located
More informationFrom 19 February 2015
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment pharmaceuticals with new active ingredients, in accordance
More informationHepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011
Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment
More informationGI DISEASE WORKSHOP CASE STUDIES
GI DISEASE WORKSHOP CASE STUDIES American Academy of Insurance Medicine Triennial Course in Insurance Medicine 2012 Clifton Titcomb Jr., MD (Hannover Re) James Topic, MD (Protective Life) 1 CASE #1 Application
More informationEffect estimates [95% CI] BOC+PegIFN/RBV vs. PegIFN/RBV
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More information2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-267, ribavirin, pegylated interferon Name of Active Ingredient: ABT-450, Ritonavir, ABT-267, Ribavirin, Pegylated interferon Individual
More informationV.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain, R. Bailey, A. Neumann, P. Cronin, J. McHutchison, E. Pulkstenis, M.
COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBINTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C V.G. Bain, P. Marotta, K. Kaita, E. Yoshida, M. Swain,
More informationfrom 29 March 2012 Effect estimates [95% CI] Telaprevir + PegIFN/RBV vs. PegIFN/RBV
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More informationOptimal ltherapy in non 1 genotypes:
Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More informationTechnology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200 NICE 2018. All rights reserved. Subject to
More informationTreatment of Chronic HCV Infection in Children and Adolescents. Guidance for Clinical Trials
Treatment of Chronic HCV Infection in Children and Adolescents Guidance for Clinical Trials Background Information Low prevalence in industrialized countries; vertical infection almost exclusive mode of
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationPeginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Part review of NICE technology appraisal guidance 75 and 106
Issue date: September 2010 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Part review of NICE technology appraisal guidance 75 and 106 National Institute for Health and Clinical
More informationIntron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description
More informationInfergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 REBETOL 200 mg capsules Pack of 84 (CIP code: 351 971.9) Pack of 112 (CIP code: 373 277.8) Pack of
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE Final Appraisal Determination Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C 1 Guidance 1.1 Combination
More informationSYNOPSIS OF RESEARCH REPORT (PROTOCOL MV22009)
SYNOPSIS OF RESEARCH REPORT 1066781 (PROTOCOL MV22009) COMPANY: F. Hoffmann-La Roche, Ltd ME OF FINISHED PRODUCT: Pegasys ME OF ACTIVE SUBSTANCE(S): Peginterferon alfa-2a (FOR TIOL AUTHORITY USE ONLY)
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Technivie GENERIC NAME Ombitasvir/paritaprevir/ritonavir MANUFACTURER AbbVie, Inc. DATE OF APPROVAL February 27, 2017 PRODUCT LAUNCH DATE Already available on the market REVIEW TYPE Review type
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 8 Last Review Date: December 18, 2017 Olysio Pegasys
More informationMEDIC CENTER. Case 2
Case 2 Case history 57 year old Vietnamese man He lives in HCM city and works as a engineer The patient presented in July 2012 with fatigue Diagnosed with HCV in 2004 Negative for both HBV and HIV antibodies
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationGlecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2
Phase 3 Treatment Naïve or Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 2 ENDURANCE-2 *ENDURANCE-2: Study Features ENDURANCE-2 Trial Design: Randomized, double-blind, placebo-controlled
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More informationApplied Health Economics and Health Policy
Applied Health Economics and Health Policy Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal Elamin H. Elbasha, Jagpreet Chhatwal,
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More information46th EASL Congress, Berlin, Germany March 30 April 3, 2011 Abstract 66
SILEN-C2: Sustained Virologic Response (SVR) and Safety of BI21335 Combined with Peginterferon Alfa-2a and Ribavirin (P/R) in Chronic HCV Genotype-1 Patients with Non-response To P/R M.S. Sulkowski, M.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationTreatment guidance for Chronic Hepatitis C Infection
Treatment guidance for Chronic Hepatitis C Infection A meeting of the network was held on 11 April 2008 at which the current evidence base for hepatitis C was reviewed. These guidelines have been produced
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationIntravenous drug use is currently the main transmission
A Prospective Controlled Study of Interferon-Based Therapy of Chronic Hepatitis C in Patients on Methadone Maintenance Stefan Mauss, 1 Florian Berger, 1 Joerg Goelz, 2 Bernhard Jacob, 3 and Günther Schmutz
More informationHepatitis C Genotype 1 (GT 1) Patients in the United States (US)
Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or
More informationStrategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany
Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer Hannover Medical School Hannover, Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Biolex,
More informationInfergen Monotherapy. Infergen (interferon alfacon-1) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.03 Subject: Infergen Monotherapy Page: 1 of 7 Last Review Date: March 13, 2014 Infergen Monotherapy
More informationPegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.08 Subsection: Anti-infective Agents Original Policy Date: January 1, 2006 Subject: Pegasys Ribavirin
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationThe treatment of choice for chronic hepatitis C is
Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon -2a (40 kd)/ribavirin Therapy Donald M. Jensen, 1 Timothy R. Morgan, 2 Patrick Marcellin, 3 Paul J. Pockros, 4 K. Rajender
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)
More informationPegylated Interferons and Ribavirins
Pegylated Interferons and Ribavirins Goal(s): Cover drugs only for those clients where there is evidence of effectiveness and safety Length of Authorization: 16 weeks plus 12-36 additional weeks or 12
More informationHepatitis C Treatment
Hepatitis C Treatment Standard of care & Managing advrse events Mohssen Nassiri Toosi, MD A s s o c i a t e P ro f e s s o r Of Internal M e d i c i n e Te h r a n U n i v e r s i t y O f M e d i c a l
More informationSynopsis Style Clinical Study Report SR EFC10139 Version number: 1 (electronic 2.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant
More informationIndividual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for
More informationSofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4
Phase 3 Treatment Experienced Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Bourlière M, et al. N Engl J Med. 217;376:2134-46. POLARIS-4: Study Features POLARIS-4 Trial Design:
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 VIRAFERONPEG 50 µg/ 0.5 ml powder and solvent for injectable solution Pack of 1 (CIP: 355 189.3)
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationBristol-Myers Squibb
A Study of the Safety and Efficacy of plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure () FINAL CLINICAL STUDY REPORT EUDRACT Number:
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationReferring to Part of Dossier: Volume: Page:
Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-333, ribavirin Name of Active Ingredient: ABT-450: (2R,6S,12Z,13aS,14aR,16aS)-N- (cyclopropylsulfonyl)-6-{[(5- methylpyrazin-2-yl)carbonyl]amino}-
More informationDOSAGE FORMS AND STRENGTHS REBETOL Capsules 200 mg (3) REBETOL Oral Solution 40 mg per ml (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (ribavirin USP) capsules, for oral
More informationIdentifying Subgroups in Product Labeling: 2 Recent Case Studies. Martin King AbbVie
Identifying Subgroups in Product Labeling: 2 Recent Case Studies Martin King AbbVie Disclosures The presentation was sponsored by AbbVie. AbbVie contributed to the design, research, and interpretation
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0145. Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationHepatitis C: Module Options for genotype 1a and 1b pros and cons
Drug Regimen HCV genotype Pros Cons Sofosbuvir 400mg + ledipasvir 90mg, orally, Sofosbuvir 400mg, orally, + daclatasvir 60mg, orally Elbasvir 50mg + grazoprevir 100mg, orally Once- single pill regimen.
More informationSupplemental Appendix. 1. Protocol Definition of Sustained Virologic Response. A patient has a sustained virologic response if:
Supplemental Appendix 1. Protocol Definition of Sustained Virologic Response A patient has a sustained virologic response if: 1. The patient is a responder at the end of treatment and all subsequent planned
More informationTECHNICAL SUMMARY OF RESULTS
TECHNICAL SUMMARY OF RESULTS 2008-004605-34 [Debio 025-HCV-205] Sponsor: Debiopharm S.A. Name of Finished Product: Tabulated Study Report (For National Authority Use Only) Name of Active Ingredient: Debio
More informationTechnivie. Technivie (ombitasvir, paritaprevir, ritonavir) and Ribavirin. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.37 Subject: Technivie Page: 1 of 6 Last Review Date: December 8, 2017 Technivie Description Technivie
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationWeight-Based Combination Therapy with Peginterferon α-2b and Ribavirin for Naïve, Relapser and Non-Responder Patients with Chronic Hepatitis C
BJID 2006; 10 (October) 311 Weight-Based Combination Therapy with Peginterferon α-2b and Ribavirin for Naïve, Relapser and Non-Responder Patients with Chronic Hepatitis C Fernando Lopes Gonçales Jr. 1,
More informationChronic Hepatitis C. Risk Factors
Chronic Hepatitis C The hepatitis C virus is one of the most important causes of chronic liver disease in the United States. Almost 4 million Americans or 1.8 percent of the U.S. population have an antibody
More informationPatients must have met all of the following inclusion criteria to be eligible for participation in this study.
Supplementary Appendix S1: Detailed inclusion/exclusion criteria Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Inclusion Criteria 1) Willing
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis B / Hepatitis C Peg-interferon Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis B / Hepatitis C Peg-interferon Hepatitis
More informationAustralasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia
Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials J Grebely
More information